Toggle Nav
Close
  • Menu
  • Setting

Recombinant Human IFN-beta1b

Catalog No.
P1149
IFN-βs are proteins produced by many cell types including lymphocytes (NK cells, B-cells and T-cells), macrophages, fibroblasts, endothelial cells, osteoblasts and others.
Grouped product items
SizePriceStock Qty
10ug
$246.00
Ship with 5-10 days
100ug
$1,057.00
Ship with 5-10 days
500ug
$2,371.00
Ship with 5-10 days
For scientific research use only and should not be used for diagnostic or medical purposes.

Tel: +1-832-696-8203

Email: [email protected]

Worldwide Distributors

Background

IFN-βs are proteins produced by many cell types including lymphocytes (NK cells, B-cells and T-cells), macrophages, fibroblasts, endothelial cells, osteoblasts and others. They have antiviral activity that it is mainly involved in innate immune response. The IFN-β family has 2 subtypes,which are IFN-β1 (IFNB1) and IFN-β3 (IFNB3) (a gene designated IFN-β2 is actually IL-6). IFN-β1 is used as a treatment for multiple sclerosis as it reduces the relapse rate.

Reference:

1. Yoshino A, Tashiro S, Ogino A, et al. 2011. Int J Oncol, 39: 529-42.

2. Farrell RA, Marta M, Gaeguta AJ, et al. 2012. Rheumatology (Oxford), 51: 590-9.

3. Breckpot K, Corthals J, Bonehill A, et al. 2005. J Leukoc Biol, 78: 898-908.

4. Oger J, Francis G, Chang P. 2005. J Neurol Sci, 237: 45-52.

5. Giorelli M, Livrea P, Trojano M. 2005. J Interferon Cytokine Res, 25: 395-406.

Description

Gene ID

3456

Accession #

P01574

Alternate Names

 

Source

Escherichia coli.

M.Wt

Approximately 20.0 kDa, a single non-glycosylated polypeptide chain containing 166 amino acids.

AA Sequence

MSYNLLGFLQ RSSNFQCQKL LWQLNGRLEY CLKDRMNFDI PEEIKQLQQF QKEDAALTIY EMLQNIFAIF RQDSSSTGWN ETIVENLLAN VYHQINHLKT VLEEKLEKED FTRGKLMSSL HLKRYYGRIL HYLKAKEYSH CAWTIVRVEI LRNFYFINRL TGYLRN

Appearance

Sterile Filtered White lyophilized (freeze-dried) powder.

Stability & Storage

Use a manual defrost freezer and avoid repeated freeze-thaw cycles.

- 12 months from date of receipt, -20 to -70 °C as supplied.

- 1 month, 2 to 8 °C under sterile conditions after reconstitution.

- 3 months, -20 to -70 °C under sterile conditions after reconstitution.

Formulation

 

Lyophilized from a 0.2 µm filtered concentrated solution in PBS, pH 7.4, containing 2 % HSA and 3 % mannitol.

Reconstitution

We recommend that this vial be briefly centrifuged prior to opening to bring the contents to the bottom. Reconstitute in sterile distilled water or aqueous buffer containing 0.1 % BSA to a concentration of 0.1-1.0 mg/mL. Stock solutions should be apportioned into working aliquots and stored at ≤ -20 °C. Further dilutions should be made in appropriate buffered solutions.

Biological Activity

Fully biologically active when compared to standard. The specific activity determined by an anti-viral assay is no less than 3.0 × 107 IU/mg.

Shipping Condition

Gel pack.

Handling

Centrifuge the vial prior to opening.

Usage

For Research Use Only! Not to be used in humans.

Shipping

Gel pack.

Quality Control

Quality Control & DataSheet

View current batch:
    Purity > 97 % by SDS-PAGE and HPLC analyses.
    Endotoxin: Less than 1 EU/µg of rHuIFN-β1b as determined by LAL method.
  • Datasheet